Albemarle Corporation (NYSE:ALB), a leading specialty chemicals company known for its lithium production crucial for electric vehicle batteries, faces significant challenges in the lithium market. UBS analyst Joshua Spector has set a price target of $57, significantly lower than its current trading price of $74.27. This target reflects a -23.25% difference, leading UBS to downgrade Albemarle to a "Sell" rating.
Despite the downgrade, Albemarle's stock recently saw a 7.2% increase, closing at $70.22, with trading volume higher than average. This rise followed a Jefferies analyst's decision to slightly lower the price target from $85 to $84 while maintaining a "Buy" rating, suggesting some analysts still see growth potential in Albemarle, despite the challenges highlighted by UBS.
Albemarle is expected to report a quarterly loss of $0.80 per share, a significant year-over-year change of -2100%. Revenues are projected to be $1.21 billion, a 15.5% decrease from the previous year. These figures are crucial for investors, as trends in earnings estimate revisions often correlate with near-term stock price movements, as highlighted by empirical research.
Albemarle's stock has seen fluctuations, with a low of $49.43 and a high of $113.91 over the past year. The current market capitalization stands at approximately $8.74 billion, with a trading volume of 5,713,302 shares.
